HK Stock Market Move | HANSOH PHARMA (03692) rose more than 3%. B7-H3 targeted antibody drug conjugate HS-20093 granted FDA breakthrough therapy designation.

HANSOH PHARMA (03692) rose more than 3%, as of the time of writing, up 3.33% to HK$16.76, with a trading volume of HK$113.42 million. On the news front, on January 7th, HANSOH PHARMA announced that GSK's GSK5764227 (GSK227), also known as HS-20093, has been granted Breakthrough Therapy designation by the US Food and Drug Administration (FDA). This B7-H3 targeted antibody-drug conjugate (ADC) is being evaluated for the treatment of relapsed or refractory osteosarcoma (bone cancer) in adult patients who have previously undergone second-line or higher therapy. HS-20093 is a novel B7-H3 targeted ADC, composed of a fully human anti-B7-H3 monoclonal antibody covalently linked with a topoisomerase inhibitor (TOPOi). It is currently being studied in multiple Phase I, II, and III clinical trials in China for the treatment of lung cancer, sarcoma, head and neck cancer, and other solid tumors.